Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug

Schallreuter, Karin U.

doi:10.1001/archderm.123.11.1494

Cited by 15 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, membrane‐associated thioredoxin reductase in psoriatic skin has been shown to react with anthralin to form a covalent anthralin‐thioredoxin reductase complex, causing irreversible enzyme deactivation 15 …”

Section: Methodsmentioning

confidence: 99%

Anthralin/dithranol in dermatology

Sehgal¹,

Verma

Khurana

2014

Int J Dermatology

View full text Add to dashboard Cite

Anthralin (1,8-dihydroxy-9anthrone, dithranol) was first synthesized as a derivative of chrysarobin, prepared from the araroba tree in Brazil over a century ago. Drawbacks to the use of anthralin include irritation and discoloration of the skin. This property of the molecule prompted workers to investigate details of its pharmacology, mode of action, and indications. The major point of this article is to highlight and revisit these aspects for pertinent future use. Therefore, it is worthwhile to consider that the drug is relatively innocuous, yet effective, and is devoid of any systemic side effects in contrast to a wide variety of systemic and topical therapies available for psoriasis and other dermatoses.

show abstract

Section: Methodsmentioning

confidence: 99%

Anthralin/dithranol in dermatology

Sehgal¹,

Verma

Khurana

2014

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…9 Changes in the levels of thioredoxin reductase in the lesional and uninvolved skin after dithranol application could be considered. 22 Furthermore, Kemeny et al . recently demonstrated that a low dose of dithranol significantly suppressed dithranol-induced mouse ear oedema, whereas it had no effect on croton oil-or dinitrofluorobenzene (DNFB)-induced dermatitis.…”

Section: Discussionmentioning

confidence: 99%

“…Their results indicated that the keratinocytes experienced tolerance (tachyphylaxis) to the antiproliferative effects of dithranol due to selective elimination of the most dithranol‐sensitive cells 9 . Changes in the levels of thioredoxin reductase in the lesional and uninvolved skin after dithranol application could be considered 22 . Furthermore, Kemeny et al .…”

Section: Discussionmentioning

confidence: 99%

Dithranol irritation in psoriasis treatment: a study of 68 inpatients

Kucharekova

Lieffers

Kerkhof

et al. 2005

Acad Dermatol Venereol

View full text Add to dashboard Cite

The irritant response of perilesional skin is a serious limitation of dithranol therapy in psoriasis. No data are available on the actual prevalence and severity of irritation during 24-h dithranol treatment in an inpatient setting. Using a retrospective analysis of 68 patients with psoriasis visiting our inpatient department for dithranol treatment, the occurrence of dithranol irritation was studied. We found a relatively high frequency of dithranol irritation. Furthermore, most irritation occurs at the start of the therapy with relatively low concentrations.

show abstract

“…The intensity of dithranol inflammation is higher in non‐lesional skin than in psoriatic plaques, 16 and dithranol‐induced inflammation occurs characteristically only in the perilesional area. It has been shown that the activity of thioredoxin reductase is much higher in psoriatic plaques compared with non‐lesional skin, suggesting that this enzyme is inducible, 17 and therefore thioredoxin reductase might well be responsible for the induction of dithranol tolerance. Further studies are necessary to clarify the exact mechanism by which superoxide anion radicals induce adaptation of the skin to dithranol.…”

Section: Discussionmentioning

confidence: 99%